Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.

Circulation Journal : Official Journal of the Japanese Circulation Society
Hiroyuki TsutsuiJ-SHIFT Study Investigators

Abstract

Increased heart rate (HR) is an independent risk factor for cardiovascular outcomes in chronic heart failure (HF). Ivabradine, anIfinhibitor, improved outcomes in patients with HF and reduced ejection fraction (HFrEF) in the SHIFT study. We evaluated its efficacy and safety in Japanese HFrEF patients in a randomized, double-blind, placebo-controlled phase III study: the J-SHIFT study. The main objective was to confirm a hazard ratio of <1 in the primary composite endpoint of cardiovascular death or hospital admission for worsening HF.Methods and Results:Patients with NYHA functional class II-IV, left ventricular EF ≤35%, and resting HR ≥75 beats/min in sinus rhythm under optimal medical therapy received ivabradine (n=127) or placebo (n=127). Mean reduction in resting HR was significantly greater in the ivabradine group (15.2 vs. 6.1 beats/min, P<0.0001). However, symptomatic bradycardia did not occur. A total of 26 (20.5%) patients in the ivabradine group and 37 (29.1%) patients in the placebo group had the primary endpoint event (hazard ratio 0.67, 95% CI 0.40-1.11, P=0.1179) during median follow-up of 589 days. Mild phosphenes were reported in 8 (6.3%) patients in the ivabradine group and 4 (3.1%) patients in the placebo grou...Continue Reading

References

Oct 13, 2005·European Heart Journal·Stuart J PocockChristopher B Granger
Jan 11, 2007·British Journal of Pharmacology·L CervettoC Gargini
Jun 15, 2007·Annals of Medicine·Richard W TroughtonM Gary Nicholls
Mar 1, 2008·Cardiovascular Drugs and Therapy·Jens RosenbergPer Rossen Hildebrandt
Nov 30, 2010·International Journal of Cardiology·C CeconiUNKNOWN BEAUTIFUL Echo-BNP Investigators
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
Dec 4, 2012·The EPMA Journal·Nobuyuki Shiba, Hiroaki Shimokawa
Jan 15, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN study investigators
Aug 22, 2017·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN J-EMPHASIS-HF Study Group
Jan 5, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Tomomi IdeHiroyuki Tsutsui

❮ Previous
Next ❯

Citations

Aug 30, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshihiro Seo, Nobuyuki Ohte
Jun 28, 2020·ESC Heart Failure·Toshihide IzumidaKoichiro Kinugawa
Feb 18, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Toyoaki Murohara
Apr 1, 2020·International Heart Journal·Hisataka Maki, Norihiko Takeda
Aug 4, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Sho OkadaYoshio Kobayashi
Aug 10, 2020·Current Cardiology Reports·Domenico D'AmarioGianluigi Savarese
Aug 4, 2020·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiYasushi Kawasaki
Nov 5, 2020·The Cochrane Database of Systematic Reviews·Carina BenstoemVincent Brandenburg
Jan 28, 2021·Clinical Drug Investigation·Shunsuke KiuchiTakanori Ikeda
Feb 5, 2021·Journal of Cardiac Surgery·Teruhiko ImamuraKoichiro Kinugawa
Apr 13, 2021·Journal of Cardiology Cases·Masakazu HoriKoichiro Kinugawa
Apr 24, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Toru KawadaMasaru Sugimachi
Oct 1, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Related Papers

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Caroline M Perry
Journal of the American Association of Nurse Practitioners
Jenna L Foster, Rodel V Bobadilla
© 2021 Meta ULC. All rights reserved